Search - tctmd.com

Displaying 241 - 260 of 422

Sort: Relevancy | Date

Novel Drug Therapies for HCM

Presentation THT 2022

Novel Drug Therapies for HCM

Presenter: Carolyn Ho

February 01, 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presentation THT 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presenter: Barry Greenberg

February 01, 2022

The Role of Genetic Testing in Heart Failure (When Should You Order It)

Presentation THT 2022

The Role of Genetic Testing in Heart Failure (When Should You Order It)

Presenter: W. H. Wilson Tang

February 01, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

January 26, 2022

A Trainee’s Perspective on the First Genetically Engineered Pig-to-Human Cardiac Xenotransplantation

News Opinion Fellow Talk

A Trainee’s Perspective on the First Genetically Engineered Pig-to-Human Cardiac Xenotransplantation

Corbin E. Goerlich, MD

January 13, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

TCTMD’s Top 10 Most Popular Stories for November 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

November 30, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

AHA Announces Fully Virtual Meeting in Light of Surging COVID-19 Numbers

News Conference News

AHA Announces Fully Virtual Meeting in Light of Surging COVID-19 Numbers

Michael O'Riordan

September 17, 2021

CMS Pays More to Male Cardiologists, but the Reasons Why Are Murky

News Daily News

CMS Pays More to Male Cardiologists, but the Reasons Why Are Murky

Michael O'Riordan

September 10, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.